1109 related articles for article (PubMed ID: 9537453)
1. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
2. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
[TBL] [Abstract][Full Text] [Related]
4. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
7. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study.
Tassopoulos NC; Vafiadis I; Tsantoulas D; Syrokosta J; Hatzis G; Delladetsima JK; Demonakou M; Sypsa V; Hatzakis AE
J Interferon Cytokine Res; 2002 Mar; 22(3):365-9. PubMed ID: 12034044
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.
Everson GT; Jensen DM; Craig JR; van Leeuwen DJ; Bain VG; Ehrinpreis MN; Albert D; Joh T; Witt K
Hepatology; 1999 Jul; 30(1):271-6. PubMed ID: 10385666
[TBL] [Abstract][Full Text] [Related]
9. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
[TBL] [Abstract][Full Text] [Related]
10. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
Farrell G; Cooksley WG; Dudley FJ; Watson K
J Viral Hepat; 1997 Sep; 4(5):317-23. PubMed ID: 9310930
[TBL] [Abstract][Full Text] [Related]
13. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
14. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
[TBL] [Abstract][Full Text] [Related]
15. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
[TBL] [Abstract][Full Text] [Related]
17. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
[TBL] [Abstract][Full Text] [Related]
18. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
19. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
[TBL] [Abstract][Full Text] [Related]
20. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
